← Back to Search

Heart transplant recipient for Heart Transplant

N/A
Waitlist Available
Led By Michael Khoury, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Summary

There are many barriers to heart-healthy lifestyles in pediatric patients with acquired and congenital heart disease. Investigators want to further understand how participants heart and skeletal muscles work together during exercise and evaluate the impact on cardiac function. To do this, the investigators will use magnetic resonance imaging (MRI) to scan the heart and skeletal muscles during exercises to assess blood flow, oxygenation and function.

Eligible Conditions
  • Heart Transplant
  • Acute Lymphoblastic Leukemia
  • Congenital Heart Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cardioplumonary Exercise Test
MRI assessment of cardiac function at rest
MRI assessment of cardiac structure at rest
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Heart transplant recipientExperimental Treatment2 Interventions
Participants aged 10-18 years who have recieved a heart transplant.
Group II: Congenital heart diseaseExperimental Treatment2 Interventions
Participants aged 10-18 years who have congenital heart disease.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiopulmonary Exercise Test
2014
N/A
~190

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
913 Previous Clinical Trials
390,413 Total Patients Enrolled
Michael Khoury, MDPrincipal InvestigatorUniversity of Alberta
2 Previous Clinical Trials
54 Total Patients Enrolled
~13 spots leftby Dec 2026